Gunhild von Amsberg
Overview
Explore the profile of Gunhild von Amsberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Amsberg G, Dyshlovoy S, Kaune M
Urologie
. 2025 Feb;
64(3):246-255.
PMID: 39928109
Aggressive variants of prostate cancer (AVPC) comprise a heterogeneous group of prostate carcinomas characterized by androgen-independent, aggressive tumor growth. Clinically, they are characterized by prostate-specific antigen (PSA)-negative progression and an...
2.
Mazzucato G, Falkenbach F, Ekrutt J, Kohler D, von Amsberg G, Cerruto M, et al.
Clin Exp Metastasis
. 2025 Jan;
42(2):13.
PMID: 39883215
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely...
3.
Tabakmakher K, Makarieva T, Sabutski Y, Kokoulin M, Menshov A, Popov R, et al.
Mar Drugs
. 2024 Sep;
22(9).
PMID: 39330277
Stonikacidin A (), the first representative of a new class of 4-bromopyrrole alkaloids containing an aldonic acid core, was isolated from the marine sponge . The compound is named in...
4.
Casuscelli J, von Amsberg G, Retz M
Urologie
. 2024 Sep;
63(10):1002-1010.
PMID: 39235511
Background: Patients with locally advanced or metastatic urothelial carcinoma face a poor prognosis. Standard first-line treatment involves platinum-based combinations followed by avelumab maintenance therapy. Follow-up therapies include enfortumab vedotin, vinflunine,...
5.
Kuzmich A, Filshtein A, Likhatskaya G, Gorpenchenko T, Chikalovets I, Mizgina T, et al.
IUBMB Life
. 2024 Aug;
76(12):1279-1294.
PMID: 39166889
Lectins are carbohydrate-binding proteins, whose biological effects are exerted via binding to glycoconjugates expressed on the surface of cells. Exposure to lectins can lead not only to a change in...
6.
Oudard S, Tran Y, Helissey C, Vauchier C, Ratta R, Bennamoun M, et al.
Eur Urol Oncol
. 2024 Aug;
8(1):126-134.
PMID: 39143002
Background And Objective: The CABASTY study showed that more frequent administration of a lower dose of cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without...
7.
Dyshlovoy S, Paigin S, Afflerbach A, Lobermeyer A, Werner S, Schuller U, et al.
Int J Cancer
. 2024 Jul;
155(12):2129-2140.
PMID: 39031959
Oxford Nanopore Technologies sequencing, also referred to as Nanopore sequencing, stands at the forefront of a revolution in clinical genetics, offering the potential for rapid, long read, and real-time DNA...
8.
Goradia N, Werner S, Mullapudi E, Greimeier S, Bergmann L, Lang A, et al.
Nat Commun
. 2024 Jun;
15(1):5241.
PMID: 38898011
While the elucidation of regulatory mechanisms of folded proteins is facilitated due to their amenability to high-resolution structural characterization, investigation of these mechanisms in disordered proteins is more challenging due...
9.
Dyshlovoy S, Mansour W, Ramm N, Hauschild J, Zhidkov M, Kriegs M, et al.
Sci Rep
. 2024 May;
14(1):11788.
PMID: 38783016
Fascaplysin is a red cytotoxic pigment with anticancer properties isolated from the marine sponge Fascaplysinopsis sp. Recently, structure-activity relationship analysis reported by our group suggested that selective cytotoxicity of fascaplysin...
10.
Leonhardt L, Heuer A, Stangenberg M, Schroeder M, Schmidt G, Welker L, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730611
Malignant spinal lesions (MSLs) are frequently the first manifestation of malignant disease. Spinal care, diagnostic evaluation, and the initiation of systemic therapy are crucial for outcomes in patients (pts) with...